Altamira Therapeutics has entered into a collaboration and option agreement with Heqet Therapeutics utilizing the Company’s proprietary OligoPhore delivery platform. Based in Turin, Italy, Heqet is a biotech spin-out from King’s College London. It is developing groundbreaking genetic medicines to reverse the damage of ischemic heart disease. Under the terms of the agreement, Heqet will test nanoparticles based on Altamira’s OligoPhore delivery platform and comprising certain non-coding RNAs in the regeneration of damaged heart tissue following myocardial infarction in animal models. Upon successful conclusion of the experiments, Heqet will, under certain conditions, have the option to negotiate with Altamira for a license to use the Company’s technology and intellectual property to translate its findings into the development of therapeutics for cardiac regeneration.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CYTO:
- Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac Regeneration
- Altamira Therapeutics files to sell common shares, no amount given
- Altamira announces FDA clearance of IND for AM-125
- One new option listing and option delistings on June 15th